Meglumine antimoniate

Meglumine antimoniate is a medicine used to treat leishmaniasis.[1] This includes visceral, mucocutaneous, and cutaneous leishmaniasis.[1] It is given by injection into a muscle or into the area infected.[1]

Meglumine antimoniate

Clinical data
Other names	Meglumine antimonate
AHFS/Drugs.com	Micromedex Detailed Consumer Information
ATC code	P01CB01 (WHO) QP51AB01 (WHO)
Identifiers
IUPAC name Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol
CAS Number	133-51-7
PubChem CID	64953
ChemSpider	58479
UNII	75G4TW236W
ChEMBL	ChEMBL239129
NIAID ChemDB	008733
CompTox Dashboard (EPA)	DTXSID4043935
ECHA InfoCard	100.004.645
Chemical and physical data
Formula	Variable
Molar mass	Variable
3D model (JSmol)	Interactive image
SMILES O=[Sb](=O)O.O[C@@H]([C@@H](O)[C@H](O)[C@@H](O)CNC)CO
InChI InChI=1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1 Key:XOGYVDXPYVPAAQ-SESJOKTNSA-M
(what is this?)  (verify)

Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pain, irregular heartbeat, and kidney problems.[1] It should not be used in people with significant heart, liver, or kidney problems.[1] It is not recommended during breastfeeding.[1] It belongs to a group of medications known as the pentavalent antimonials.[1]

Meglumine antimoniate came into medical use in 1946.[2] It is on the World Health Organization's List of Essential Medicines.[3] It is available in Southern Europe and Latin America but not the United States.[4][5]

Society and culture

It is manufactured by Aventis[6] and sold as Glucantime in France, and Glucantim in Italy.

See also

• Meglumine

References

1. World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 183. hdl:10665/44053. ISBN 9789241547659.
2. Sneader, Walter (2005). Drug Discovery: A History. John Wiley & Sons. p. 59. ISBN 9780470015520. Archived from the original on 2016-12-20.
3. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
4. Bope, Edward T.; Kellerman, Rick D.; Rakel, Robert E. (2010). Conn's Current Therapy 2011: Expert Consult. Elsevier Health Sciences. p. 95. ISBN 978-1437735727. Archived from the original on 2016-12-20.
5. Gorbach, Sherwood L.; Bartlett, John G.; Blacklow, Neil R. (2004). Infectious Diseases. Lippincott Williams & Wilkins. p. 355. ISBN 9780781733717. Archived from the original on 2016-12-20.
6. Aventis press release Archived 2014-05-22 at the Wayback Machine, 15 April 2005. (in German)

External links

• "Meglumine antimoniate". Drug Information Portal. U.S. National Library of Medicine.